Tuesday, September 04, 2007 7:42:54 AM
Companies Committed to Advancing Reproductive Medicine
ViaCell, Inc. (Nasdaq:VIAC) announced today it has entered into an agreement under which EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, will provide support related to the clinical development of ViaCyteSM, ViaCell’s investigational product for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. In addition, EMD Serono has agreed to provide certain quantities of two of its products, Gonal-f® RFF Pen (follitropin alfa injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection), for the treatment of patients participating in the ViaCyte study. Financial terms were not disclosed.
“We are delighted to have EMD Serono, a leader in fertility health, supporting the clinical development of ViaCyte,” said Marc D. Beer, President and Chief Executive Officer of ViaCell. “This collaboration provides us with important support and gives us access to a wealth of knowledge and experience as we advance ViaCyte through our pivotal trial and toward commercialization.”
“We believe oocyte cryopreservation has the potential to continue to drive the evolution of reproductive medicine and research from a historical focus of infertility to fertility preservation,” stated Fereydoun Firouz, President of EMD Serono, Inc. “EMD Serono looks forward to collaborating with companies such as ViaCell, to support advancements in reproductive medicine including the investigation of different technologies that may lead to new discoveries for patients.”
ViaCell commenced a pivotal clinical trial evaluating ViaCyte in March 2007. The primary objective of the pivotal study is to determine the efficacy of the ViaCyte media for the cryopreserving and thawing of human oocytes. The open-label study will also evaluate safety. Women seeking IVF, diagnosed with male factor infertility, are eligible to enroll. The primary efficacy endpoint is live birth rate and 50 live births must be achieved. Approximately 300 healthy women, age twenty-one to thirty-five, who are currently seeking fertility treatment, are expected to enroll in the study. Participants in the ViaCyte clinical trial will undergo traditional in vitro fertilization (IVF). Women enrolled in the study will receive FSH to stimulate the development of egg-containing follicles in the ovaries and r-hCG to induce the release of mature eggs from the ovaries. The oocytes recovered will be cryopreserved using ViaCyte. The oocytes will be thawed following storage in liquid nitrogen and subsequently inseminated. Embryos will be transferred to the subject’s uterus using a non-surgical procedure. Additional information about the trial is available online at http://www.clinicaltrials.gov.
About ViaCyte
ViaCyte is an investigational product intended to broaden reproductive options for women through the cryopreservation and thawing of human oocytes. The oocyte is a large cell with a high content of water, historically making it difficult to freeze. ViaCell’s proprietary technology to cryopreserve and thaw human oocytes uses a choline chloride-based media designed to protect the cells from damage during the freezing process with the goal of making it possible to successfully store and thaw oocytes for future use. There is currently no FDA-cleared product for oocyte cryopreservation.
About ViaCell
ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.
This press release contains forward-looking statements regarding the clinical development and potential of ViaCyte. Such statements are based on management's current expectations. Successful completion of the ViaCyte clinical trial and the potential for ViaCyte are subject to a number of risks and uncertainties which could cause actual results to differ materially from the Company's current expectations. For example, there is no assurance that the results of the clinical trial will show that ViaCyte is safe and effective in the preservation and storage of oocytes. ViaCell may not be able to enroll a sufficient number of patients in the clinical trial or to enroll patients as rapidly as we expect. ViaCell may not be able to generate a sufficient number of live births. ViaCell may encounter safety issues. Manufacturing the ViaCyte media is a complex process. We may be unable to have the ViaCyte media consistently manufactured to specifications. Even if the data from the clinical trial is positive, there is no assurance that the FDA will agree that ViaCell has met the standards for 510(k) clearance, ViaCell’s specified regulatory pathway for ViaCyte. The FDA could at any time determine that ViaCyte will require pre-marketing authorization, which would involve additional trials, time and expense. There is no assurance that the FDA will ever approve the product. Even if approved, there is no assurance that ViaCyte will achieve commercial success or be able to successfully compete with other oocyte cryopreservation and IVF products. Drug and device development involves a high degree of risk. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors” in the Company's report on Form 10-Q for the quarter ended June 30, 2007, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.
ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc. Gonal-f® and Ovidrel® are registered trademarks of EMD Serono or its affiliates.
ViaCell, Inc.
Justine E. Koenigsberg, 617-914-3494
Senior Director, Corporate Communications
Source: Business Wire (September 4, 2007 - 6:34 AM EST)
News by QuoteMedia
www.quotemedia.com
Recent PARA News
- PARAMOUNT+ RENEWS ORIGINAL ANIMATED PRESCHOOL SERIES DORA FOR A SECOND SEASON • PR Newswire (US) • 04/24/2024 02:00:00 PM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News • IH Market News • 04/15/2024 11:06:48 AM
- Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News • IH Market News • 04/12/2024 11:05:29 AM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- Paramount Global Declares Quarterly Cash Dividend • PR Newswire (US) • 04/10/2024 08:15:00 PM
- Paramount Global to Report First Quarter Financial Results on April 29, 2024 • PR Newswire (US) • 04/09/2024 08:15:00 PM
- Shopsense AI Launches Retail Media Platform for Broadcasters • Business Wire • 04/05/2024 12:00:00 PM
- Exxon Mobil Forecasts Earnings Decline, Twilio Seeks Board Tenure Changes, and More News • IH Market News • 04/04/2024 11:30:20 AM
- Cal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and More • IH Market News • 04/03/2024 11:12:20 AM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- NICKELODEON SERVES UP BRAND-NEW EPISODES OF THE TINY CHEF SHOW BEGINNING MONDAY, APRIL 8 • PR Newswire (US) • 03/25/2024 03:00:00 PM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- PARAMOUNT+ ANNOUNCES LAUNCH TIMING AND PRICING FOR INTERNATIONAL ADVERTISING-SUPPORTED & PREMIUM SUBSCRIPTION PLANS • PR Newswire (Canada) • 03/19/2024 01:05:00 PM
- Paramount Global's Chief Financial Officer Naveen Chopra to Participate in the 2024 Morgan Stanley Technology, Media & Telecom Conference • PR Newswire (US) • 02/29/2024 09:15:00 PM
- Snowflake Stock Plummets 20.3% After CEO Transition; C3.ai, Okta, and Duolingo Surge Post-Strong Quarterly Reports, and More • IH Market News • 02/29/2024 11:09:45 AM
- Paramount Global Reports Fourth Quarter and Full Year 2023 Earnings Results • PR Newswire (US) • 02/28/2024 09:00:00 PM
- Paramount Global Declares Quarterly Cash Dividends • PR Newswire (US) • 02/22/2024 09:30:00 PM
- Cisco Systems Stock Drops 5% Following Restructuring Plan, Berkshire Trims Apple Stake, and Latest News • IH Market News • 02/15/2024 11:34:25 AM
- Paramount's Content for Change Delivers Impactful Initiatives in Las Vegas • PR Newswire (US) • 02/13/2024 02:02:00 AM
- PARAMOUNT PICTURES ANNOUNCES RENEWAL OF MULTI-YEAR FIRST LOOK DEAL WITH RYAN REYNOLDS' PRODUCTION COMPANY MAXIMUM EFFORT • PR Newswire (US) • 02/08/2024 05:45:00 PM
- OTOY Launches Groundbreaking Multi-Hour Star Trek Spatial Experience for the Apple Vision Pro, in Partnership with Paramount Game Studios and Roddenberry Entertainment • PR Newswire (US) • 02/02/2024 06:22:00 PM
- NICKELODEON AND CBS SPORTS REVEAL DETAILS FOR SLIME-FILLED SUPER BOWL LVIII ALTERNATE TELECAST • PR Newswire (US) • 02/01/2024 05:23:00 PM
- Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More • IH Market News • 01/31/2024 11:28:17 AM
- Wall Street Highlights: Intel’s Disappointing Quarterly Forecast, PayPal’s New AI Solutions for Merchants, and More • IH Market News • 01/26/2024 01:45:22 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM